INDEMNIFICATION AGREEMENTIndemnification Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (the “Agreement”) is made and entered into this ___ day of _______, 2018, by and between Aquestive Therapeutics, Inc., a Delaware corporation (the “Company,” which term shall include, where appropriate, any Enterprise (as hereinafter defined) controlled directly or indirectly by the Company), and __________ (the “Indemnitee”).
EXECUTIVE EMPLOYMENT AGREEMENTRegistration Rights Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY AND CONSENTCredit Agreement and Guaranty and Consent • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 2 TO CREDIT AGREEMENT AND GUARANTY AND CONSENT, dated as of May 21, 2018 (this “Amendment”), is among Aquestive Therapeutics, Inc., a Delaware corporation (the “Borrower”), the Lenders party hereto (the “Lenders”) and Perceptive Credit Holdings, LP, a Delaware limited partnership, as administrative agent and collateral agent for the Lenders (in such capacity, together with its successors and assigns, “Administrative Agent”). Reference is made to the Credit Agreement and Guaranty, dated as of August 16, 2016 (as amended, modified, restated and supplemented, the “Credit Agreement”), among the Borrower, the Subsidiary Guarantors party thereto, the Lenders parties thereto and the Administrative Agent. Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement, as amended hereby.
DATED AUGUST 15, 2008Commercial Exploitation Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, RB wishes to engage MSX to manufacture and supply the Products (as defined below) on the terms of this Agreement and MSX wishes to manufacture and supply the Products to RB on the terms of this Agreement.
AGREEMENTAgreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”), dated as of September 24, 2017, is by and between MonoSol Rx, LLC, a Delaware limited liability company (“MonoSol”); and Indivior Inc., a Delaware corporation, and Indivior UK Limited, a corporation organized under the laws of England and Wales, as successors in interest to Reckitt Benckiser Pharmaceuticals Inc. and RB Pharmaceuticals Limited, respectively (collectively, “Indivior”).
WARRANT CERTIFICATE AND AGREEMENTWarrant Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
CREDIT AGREEMENT AND GUARANTY dated as of August 16, 2016 between MONOSOL RX, LLC as Borrower, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and PERCEPTIVE CREDIT HOLDINGS, LP, as Administrative...Credit Agreement and Guaranty • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
Credit Agreement and Guaranty, dated as of August 16, 2016 (this “Agreement”), among MonoSol Rx, LLC, a Delaware limited liability company (“Borrower”), the Subsidiary Guarantors from time to time parties hereto, the Lenders from time to time parties hereto and Perceptive Credit Holdings, LP, a Delaware limited partnership, as administrative agent and collateral agent for the Lenders (in such capacity, together with its successors and assigns, “Administrative Agent” ).
STOCK OPTION AGREEMENT AQUESTIVE THERAPEUTICS, INC.Stock Option Agreement Aquestive Therapeutics • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS STOCK OPTION AGREEMENT (this “Agreement”) between Aquestive Therapeutics, Inc. (the “Corporation” or the “Company”) and [______] (the “Optionee”) is made as of [______], 2018 (the “Grant Date”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 24, 2018 (the “Effective Date”), is by and among Aquestive Therapeutics, Inc., a Delaware corporation (the “Corporation”), Aquestive Partners, LLC, a Delaware limited liability company (“APL”), the holders of membership interests of APL (the “Membership Interests”) that are signatories hereto (each, a “Member”, and collectively, the “Members”), the members of the board of directors of APL (the “Directors”), and each of the other holders of Registrable Securities who at any time become a party hereto (the “Other Holders”). Except as otherwise indicated herein, capitalized terms used herein are defined in Section 8 hereof.
CONFIDENTIAL LICENSE AGREEMENT by and between MONOSOL RX, LLC and CYNAPSUS THERAPEUTICS INC. Dated as of April 1, 2016License Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This LICENSE AGREEMENT (together with any Schedules hereto, this “Agreement”) is entered into as of April 1, 2016 (the “Effective Date”) by and between MonoSol Rx, LLC, a Delaware limited liability company (“Licensor”), and Cynapsus Therapeutics Inc., a Canadian corporation (“Licensee”). Licensor and Licensee are sometimes referred to hereinafter individually as a “Party” and collectively as the “Parties.”
OMNIBUS AMENDMENT NO. 12016 Warrant Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
This OMNIBUS AMENDMENT NO. 1, dated as of January 1, 2018 (this “Amendment”), is among MonoSol Rx, LLC, a Delaware limited liability company (to be renamed Aquestive Therapeutics, Inc. and converted into a Delaware corporation upon consummation of the Conversion Transaction (as defined below)) (the “Borrower”), the Lenders party hereto (the “Lenders”) and Perceptive Credit Holdings, LP, a Delaware limited partnership, as administrative agent and collateral agent for the Lenders (in such capacity, together with its successors and assigns, “Administrative Agent”). Reference is made to the Credit Agreement and Guaranty, dated as of August 16, 2016 (as amended, modified, restated and supplemented, the “Credit Agreement”), among the Borrower, the Subsidiary Guarantors party thereto, the Lenders parties thereto and the Administrative Agent. Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement, as amended hereby.
INDUSTRIAL LEASE AGREEMENT by and betweenIndustrial Lease Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Indiana
The parties to this Agreement, entered into on October 24th, 2006, between ASHLAND NORTHWEST PARTNERS L.P., hereafter referred to as “Landlord”, and MONOSOL Rx, LLC hereinafter referred to as “Tenant”, agree as follows:
AGREEMENT TO TERMINATE CLAAgreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement to Terminate CLA (“Agreement”), dated as of March 20, 2012 (the “Effective Date”), is between KemPharm, Inc., an lowa corporation with its principal offices at 7 Hawkeye Drive, Suite 103, North Liberty, Iowa 52317 (“KemPharm”), and MonoSol Rx, LLC, a Delaware limited liability company with its principal offices at 30 Technology Drive, Warren, New Jersey 07059 (“MSRx”).
